Navigation Links
Orexigen(R) Therapeutics Names Michael Scaife Senior Vice President of Regulatory Affairs and Product Development, Contrave(R) Program
Date:4/27/2009

SAN DIEGO, April 27 /PRNewswire-FirstCall/ -- Orexigen(R) Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, today announced that Michael C. Scaife, Ph.D., has joined the organization as Senior Vice President of Regulatory Affairs and Product Development, Contrave(R) Program.

"Michael brings to Orexigen over 26 years of solid experience in biotechnology and pharmaceutical product development, including 15 successful product approvals by the FDA," said Michael Narachi, the Company's President and Chief Executive Officer. "His appointment is timely as our foremost priority is to submit to the FDA the highest quality NDA and bring Contrave, our lead obesity product candidate, to market expeditiously."

In his role, Dr. Scaife will lead the development of Contrave (naltrexone sustained release (SR)/bupropion SR), which is on track for submission to the FDA in the first half of 2010. "I'm thrilled to join the Orexigen team, and I believe my development and regulatory experience will be invaluable as the Company works to help fill a significant unmet need in the fight against obesity," said Dr. Scaife.

Dr. Scaife has worked in leadership roles for a variety of device, drug and biopharma companies in both Europe and the United States. Prior to joining Orexigen, Dr. Scaife was Principal of MChS Consultancy Inc., a leading pharmaceutical development services agency. He also served as Senior Vice President of Global Regulatory Affairs, Pharmacovigilance and Drug Safety, Drug Information Services, Compliance and Quality Operations at Chiron Biopharma. In addition, Dr. Scaife held the position of Vice President of Quality and Regulatory Affairs for Nektar Therapeutics, Vice President of Global Regulatory Affairs for Elan Pharmaceuticals, and various regulatory an
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Orexigen(R) Therapeutics Schedules March 12, 2009 Webcast Discussion of Financial Results for the Fourth Quarter and Year Ended December 31, 2008
2. Orexigen(R) Therapeutics to Speak at BIO CEO & Investor Conference
3. Orexigen(R) Therapeutics Announces First of Four Phase 3 Trials of Contrave(R) Meets Co-Primary and Key Secondary Endpoints
4. Orexigen(R) Therapeutics Issued a Key Fourth U.S. Patent on Contrave(R)
5. Orexigen(R) Therapeutics Announces Third Quarter 2008 Financial Results
6. Orexigen(R) Therapeutics Initiates First Clinical Trial of OREX-003 for the Mitigation of Antipsychotic-Associated Weight Gain
7. Orexigen(R) Therapeutics Appoints Dennis Kim, M.D., as Senior Vice President, Head of Obesity and Metabolic Disorders
8. Orexigen(R) Therapeutics to Present at Upcoming Investor Conferences
9. Orexigen(R) Therapeutics Schedules Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2008
10. OREXIGEN(R) Therapeutics Receives Notice of Allowance for U.S. Patent Covering the Composition of Matter in OREX-003
11. United Therapeutics to Announce 2009 First Quarter Financial Results Before Market Open on Friday, May 1, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... 2015 Research and Markets( http://www.researchandmarkets.com/research/3nl6s2/neuroprotection ) ... report "Neuroprotection - Drugs, Markets and Companies" ... describes the role of neuroprotection in acute disorders ... system as well as in chronic diseases such ... mechanisms of damage to neural tissues are similar ...
(Date:5/28/2015)... 2015 Natera, Inc., a leader in ... in Ultrasound in Obstetrics & Gynecology ... prenatal test (NIPT) can identify a complete molar ... A study based upon data collected in the ... about 1 in 1,000 pregnancies, although other studies ...
(Date:5/28/2015)... 28, 2015  PDS Biotechnology Corp. announces preliminary ... targeting HPV-16, has generated strong T-cell responses in ... cancer is treated by surgical removal of lesions ... non-surgical alternative. Results show that it primes and ... target, and kill precancerous and cancerous cells that ...
(Date:5/28/2015)... -- GenVec, Inc. (Nasdaq: GNVC ) today announced that ... will present a company overview at the Jefferies 2015 ... June 4, 2015. The live and ... at the following link:  http://wsw.com/webcast/jeff88/gnvc .  This link ... visit www.genvec.com , click on "Investors and Media" ...
Breaking Biology Technology:Global Neuroprotection Market Report 2015-2024 - Drugs, Markets and Companies 2Global Neuroprotection Market Report 2015-2024 - Drugs, Markets and Companies 3First Confirmed Detection of a Complete Molar Pregnancy with Cell-Free DNA Test 2First Confirmed Detection of a Complete Molar Pregnancy with Cell-Free DNA Test 3PDS Biotechnology reports positive Phase I clinical trial results in proprietary HPV-Cancer Immunotherapy 2GenVec To Present At The Jefferies Healthcare Conference 2
... antibiotic surgical product may reduce incidence of surgical ... reduce post-operative cost and complications, DEERFIELD, Ill. ... today announced a licensing agreement with,Innocoll Pharmaceuticals Ltd, ... to market and distribute the company,s gentamicin surgical,implant ...
... Mymetics,Corporation (OTC: MYMX), will be holding an important conference ... York Time to update all shareholders,on the recent progress ... and to,address recent press articles., You may join ... PIN 815,726 and from Europe at +41-800-329-326 PIN 815 ...
... COUNTY, Calif., Aug. 22 Beckman,Coulter, Inc. (NYSE: ... marketer,of products that simplify, automate, and innovate complex ... senior vice,president and chief financial officer, will present ... September 4, 2008 at 8:00 a.m.,(ET)., (Logo: ...
Cached Biology Technology:Baxter Announces Licensing Agreement for Innocoll's Gentamicin Surgical Implant in the United States 2Baxter Announces Licensing Agreement for Innocoll's Gentamicin Surgical Implant in the United States 3Baxter Announces Licensing Agreement for Innocoll's Gentamicin Surgical Implant in the United States 4
(Date:5/20/2015)... , May 20, 2015 /PRNewswire/ ... http://www.researchandmarkets.com/research/h8t4x6/5year ) has announced the addition ... the Global Iris Recognition Market"  report ... , ,This research service analyses trends ... the government and commercial sectors, globally. ...
(Date:5/19/2015)... , May 19, 2015 ... announced the addition of the  "Genetic Testing ... ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,A recent report, ... in-depth analysis of the current and future ... gene-based tests, their working principles and types ...
(Date:5/11/2015)... Calif. , May 11, 2015  Synaptics ... of human interface solutions, today announced the appointment ... President and Chief Financial Officer, reporting to ... replaces Synaptics, current Chief Financial Officer, Kathleen ... 2014. Mr. Ali brings extensive ...
Breaking Biology News(10 mins):Global Iris Recognition Market Report 2015 - 5-Year Opportunity Analysis 2Global Genetic Testing Market Outlook 2018 2Synaptics Appoints Wajid Ali as Senior Vice President and Chief Financial Officer 2
... diagnosing and treating disease with particles so small that ... ― will deliver the inaugural presentation in "The Kavli ... National Meeting of the American Chemical Society (ACS). ... that Christy L. Haynes, Ph.D., will deliver the lecture ...
... Polytechnic University of Valencia and the University of Oxford have ... cream coloured cup than in a white or red one. ... perceive food in a different way depending on the characteristics ... "The colour of the container where food and drink ...
... team of researchers that has unlocked the "black box" to the ... peek inside, recently published in the Proceedings of the National ... journals in the world may well explain how the number ... "The organisms that live in soil do all kinds of important ...
Cached Biology News:Nanoparticle researcher will inaugurate prestigious 'emerging leaders' lecture series 2Nanoparticle researcher will inaugurate prestigious 'emerging leaders' lecture series 3Cup color influences the taste of hot chocolate 2Biologists unlock 'black box' to underground world 2
... IT siRNA Tracker Intracellular Localization Kit provides ... and deliver siRNA, of your design, in ... vitro tracking experiments. Subcellular localization and functional ... monitored following introduction of the labeled siRNA ...
... IT siRNA Tracker Intracellular Localization Kit provides ... and deliver siRNA, of your design, in ... vitro tracking experiments. Subcellular localization and functional ... monitored following introduction of the labeled siRNA ...
... CLS number is a new ... match Cornings product number. If ... order under the old Sigma-Aldrich ... service for assistance. ID clarifier: ...
... (ECM) is an important step in tumor ... adhering to and spreading along the blood ... MMP collagenases, dissolve tiny holes in the ... vessels to allow cancer cells to invade.,The ...
Biology Products: